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Abstract
Adeno-Associated Virus based vectors (rAAV) are advantageous for human gene therapy due to
low inflammatory responses, lack of toxicity, natural persistence, and ability to transencapsidate
the genome allowing large variations in vector biology and tropism. Over sixty clinical trials have
been conducted using rAAV serotype 2 for gene delivery with a number demonstrating success in
immunoprivileged sites, including the retina and the CNS. Furthermore, an increasing number of
trials have been initiated utilizing other serotypes of AAV to exploit vector tropism, trafficking,
and expression efficiency. While these trials have demonstrated success in safety with emerging
success in clinical outcomes, one benefit has been identification of issues associated with vector
administration in humans (e.g. the role of pre-existing antibody responses, loss of transgene
expression in non-immunoprivileged sites, and low transgene expression levels). For these
reasons, several strategies are being used to optimize rAAV vectors, ranging from addition of
exogenous agents for immune evasion to optimization of the transgene cassette for enhanced
therapeutic output. By far, the vast majority of approaches have focused on genetic manipulation
of the viral capsid. These methods include rational mutagenesis, engineering of targeting peptides,
generation of chimeric particles, library and directed evolution approaches, as well as immune
evasion modifications. Overall, these modifications have created a new repertoire of AAV vectors
with improved targeting, transgene expression, and immune evasion. Continued work in these
areas should synergize strategies to improve capsids and transgene cassettes that will eventually
lead to optimized vectors ideally suited for translational success.
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Gene therapy has the potential to cure genetic diseases and to allow the long-term, non-
invasive treatment of acquired diseases in humans. Through therapeutic gene transfer,
genetic diseases could be cured by gene addition, addition of a functional copy of the
defective gene, while, acquired disease could be treated by the introduction of genes to
synthesize therapeutic proteins or encoding of therapeutic RNAs (shRNA). Worldwide,
approximately 1500 gene therapy clinical trials have been approved to date and, although
the majority are phase I trials, approximately four percent are phase III trials. These trials are
focused on many areas of disease including monogenetic disease, cancer, cardiovascular
disease, neurological diseases, and ocular disease (wiley.co.uk/genetherapy/clinical). With
the promising results of initial clinical trials, understanding of the various strategies for gene
delivery and of the design of vectors to improve clinical efficacy has become increasingly
important. In this review, we will discuss the potential of Adeno-Associated Virus vectors
(rAAV) as a gene delivery vector, including rAAV's current clinical use and new strategies
to create better AAV vectors and increase the efficacy of rAAV based gene therapy. Gene
delivery strategies can be generally divided into the categories of non-viral and viral
strategies.
1.1. Non-Viral Gene Delivery Strategies
Non-viral strategies can include chemical techniques, such as the use of “naked” nucleic
acid and the use of cationic carriers, and more biological carriers, such as biologic
membranes, bacteria, and virus-like particles (VLPs). The simplest strategy for gene transfer
is the use of naked nucleic acids and several studies have examined the uses of naked DNA
[1] or RNA [2] for in vivo gene delivery. Although this technique has the advantage of
simplicity, unprotected nucleic acids are generally impractical for in vivo use due to rapid
degradation, low transfection levels, and lack of tissue targeting ability; however, delivery
methods such as hydrodynamic injection can increase the success rate [3].
An additional, more complex, chemical strategy for the gene delivery is the use of cationic
lipid or polymer carriers to deliver nucleic acids in a more efficient manner. Some of the
recent advances with these techniques have been reviewed [4-6]. Many of these carriers
were adapted for in vivo use in order to avoid early problems with viral vectors, such as
immune responses and toxicity; however, cationic carriers generally suffer from low
efficiency of transfection. One problem that has occurred with cationic carriers is an
inability to control the condensation state of the DNA, leading to decreased stability and
decreased transcriptional activity of the delivered DNA [7]. Strategies to increase the
uniformity of DNA condensation include the creation of non-uniform polymers and the use
of a mix of polymers. In addition, cationic complexes generally promiscuously bind to
proteins, leading to very low circulation times in vivo. Although the addition of polyethylene
glycol (PEG) to the complexes (PEGylation) can increase circulation times, this generally
leads to lower gene expression than is observed with non-PEGylated complexes [8].
Furthermore, cationic complexes have no ability to target specific tissues. Targeting ligands
can be added to the complexes; however, can increase immune responses and change in
intracellular trafficking [9]. Finally, the cationic carriers do not avoid innate immune
responses by DNA sensors and can lead to long-term changes in cellular gene expression
and differentiation profiles [10]. For all of these reasons, more biological gene delivery
systems have been sought.
Several biological, non-viral gene delivery systems, including bactofection, biological
liposomes, and virus-like particles, have now been developed and have been more
rigorously reviewed [11]. Bactofection utilizes attenuated bacteria to deliver DNA, mRNA,
or a therapeutic protein to its host cell [12-14]. The advantages of bactofection include the
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rapid and inexpensive production of many species of bacteria, wide variety in tropism,
accommodation of multiple types and sizes of “genetic cargo”, strategies of immune
evasion, and control by antibiotics. Nevertheless, this strategy often leads to low levels of
transgene expression [15], immune responses to conserved molecular motifs, toxicity [12,
15], and the production of inhibitory antibodies [16], as well as the possibility of preexisting
immunity to the bacterial vector.
Other biological carriers that have been considered for in vivo gene delivery are biological
liposomes such as erythrocyte ghosts and secretion exosomes. The liposomes can be derived
from the subject to be treated to avoid immune responses; however, this also inhibits large-
scale production, as carriers for each subject would need to be made individually. Further
advantages of biological liposomes include easy loading of nucleic acid cargo [17] and high
stability [18]. However, these carriers have limited endothelial permeability and are in very
early stages of development.
One final non-viral gene delivery strategy is the use of virus-like particles (VLP), or empty
viral particles. VLPs are produced by transfecting cells with only the structural genes of a
virus and harvesting the empty particles. The particles can then be loaded ex vivo with
normal or modified nucleic acids, such as locked nucleic acid (LNA) [19]. In addition, VLPs
are generally easier to purify than their genome containing parent virus [20]. These particles
generally exhibit the same characteristics as their parent virus; however, low loading
efficiency and strong immune responses [21, 22] hinder their practical application for gene
therapy.
1.2. Viral Gene Delivery Strategies
The difficulties with non-viral gene delivery systems in vivo highlight the importance of
viral gene delivery systems (viral vectors) for clinical gene therapy. At least sixteen different
viruses are being used for gene delivery in clinical trials; however, viruses used for gene
delivery can be separated into several categories: non-mammalian viruses, oncolytic
mammalian viruses, and general mammalian viruses. The two most common types of non-
mammalian viruses used for gene delivery are Baculoviruses and bacteriophage.
Baculoviruses’ natural hosts are insects, but these viruses can transduce mammalian cells
and have a long-standing history of use in vitro [23]. These vectors can accommodate large
transgenes, have easily scalable production, are not replica-tive in mammalian cells and are
not toxic [24], have no preexisting immunity in humans [25], and can transduce stem cells
[26]. Unfortunately, Baculovirus vectors tend to elicit strong innate and adaptive immune
responses [27], are inactivated by the complement serum proteins [28], elicit some viral
gene expression [29], allow for only transient transgene expression [30], and have
demonstrated limited efficacy in vivo [30, 31]. Thus, although Baculoviruses are highly
efficient vectors in vitro, they require further development to exploit their full potential for
in vivo use. Bacteriophage, on the other hand, tend to be highly stable [32], be
nonpathogenic to eukaryotic cells [33], have flexible packaging capacities [34], allow the
use of targeting ligands [35], and be easy and inexpensive to produce. However, these
vectors tend to degrade quickly in vivo [36] and are highly immunogenic [33]. Until these
critical issues are resolved, mammalian viruses may be better options for in vivo gene
delivery, as they have evolved to be successful in mammalian environments.
An area of increasing clinical interest is the use of gene therapy to treat cancer. One strategy
to target gene therapy to cancer cells employs an oncolytic virus to deliver a transgene to
enhance tumor cell cytotoxicity; these viruses have been recently, thoroughly reviewed [37,
38]. Oncolytic viruses have a natural cytotoxicity to cancer cells and their selectivity for
these cells is often enhanced by mutations that inhibit their replication in other cell types. In
addition, the insertion of cytotoxic transgenes, such as Herpes Virus thymidine kinase, into
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these viruses can greatly enhance their killing of cancer cells [39]. Specifically, viruses with
the capacity to be oncolytic include Herpes Simplex Virus [40], Adenovirus [41, 42],
Reoviruses [43], Vesicular Stomatitis Virus [39] and Measles Virus [44, 45]. In fact, an
Adenovirus vector has been approved as a therapeutic for head and neck cancer in China
[46]. Furthermore, a Reovirus vector called Reolysin® [47] marketed by Oncolytic Biotech,
Inc was recently approved for phase III clinical trials in the UK and the USA. The use of
oncolytic viruses for gene delivery is a very beneficial strategy for cancer gene therapy;
however, other strategies are necessary for other gene therapy applications.
The final category of viral gene delivery vectors are general mammalian viral vectors, the
most common of which are Adenovirus, lentiviruses, and Adeno-Associated Virus (AAV).
Adenovirus was developed early as a gene delivery vector and is still the most common
vector used for gene therapy clinical trials. The use of adenovirus as a gene delivery vector
has been thoroughly reviewed [48]. Adenoviral vectors have the advantages of efficient
transduction of dividing and non-dividing cells, high transgene capacity, high stability in
blood, and low insertional mutagenesis rates. However, they are highly immunogenic and
inflammatory, are subject to preexisting immunity, and are generally diverted from
circulation to the liver [48]. The high inflammatory reaction and immunogenisity make these
viruses ideal for cancer immunotherapy and vaccine applications. Another very commonly
used class of mammalian viruses for gene therapy is lentiviral vectors based on complex
retroviruses such as HIV or SIV [49]. These viruses can transduce non-dividing cells [50],
permit pseudotyped (packaged into an envelope containing proteins of another virus) [51],
and demonstrate less tendency to integrate into transcriptionally active genes than other
retrovirus [52]. Conversely, lentiviral vectors still demonstrate the possibility of insertional
mutagenesis [53], are subject to transgene silencing and variation due to integration site
[54], are subject to innate immune responses and to preexisting immunity to the
pseudotyped proteins [55], lack scalable production, and have difficulties with appropriate
animal models [56]. However, lentiviral vectors have been successfully applied to the
treatment of X-linked adrenoleukodystrophy (ALD) through ex vivo transduction of
hematopoietic stem cells in a phase I clinical trial [57]. Through ex vivo transfer, cells can
be screened for vector integration sites. In addition, integration deficient viruses are
currently in development [58, 59]. This result demonstrates the great promise of lentiviral
vectors.
Another common mammalian viral vector is Adeno-Associated Virus, which will be
discussed in the remainder of this review. AAV is not associated with any disease or
pathology and is non-inflammatory and non-toxic in humans [60]. In addition, this virus
naturally persists in many tissues, allowing for long-term transgene expression [61].
Furthermore, the ability to package AAV serotype 2 (AAV2) based transgenes in capsids
from a variety of serotypes (transencapsidation) creates vectors with widely varied tropism
[62]. All of these factors make AAV an ideal vector for gene therapy.
1.3. Adeno-Associated Virus Biology
AAV was first discovered as a contaminating virus in stocks of Adenovirus [63]. This virus
was later classified as a member of the family Parvoviridae and, as it cannot replicate
without the presence of a helper virus, a member of the Dependovirus genera. Since the
initial discovery of AAV, many different serotypes of AAV, having between 49% and 99%
identity in capsid protein amino acid sequence, have been isolated within human tissues and
within the tissues of many other animals [64]. Although the most commonly used serotype
in clinical trials to date is AAV2, several other sero-types are becoming more prevalent,
including AAV1, AAV6, AAV8, and AAVrh.10, an AAV isolated from rhesus macaques.
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The AAV genome consists of a linear 4.7 kb single-stranded DNA molecule that can be
either positive or negative sense. Inverted terminal repeats (ITRs), present at both ends of
the genome, serve as an origin of replication for the viral DNA and as integration elements
[65]. In addition, the genome consists of two genes, Rep and Cap, that, together, encode for
seven proteins. The Rep gene encodes the four non-structural proteins of the virus—Rep78,
Rep68, Rep52, and Rep40—through alternative promoters and splicing vari ants. The
functions of the Rep proteins include genome replication, transcriptional control, integration,
and genome encapsidation [66, 67]. Although it is known that the large Reps (Rep78 and
Rep68) function in the nicking and unwinding of the ITRs, the functions of the small Reps
(Rep52 and Rep40) are not yet clear. The other gene, Cap, encodes the structural proteins of
the virus—VP1, VP2, and VP3—through splicing and start codon variants. VP1, VP2, and
VP3, all share the common VP3 region, while VP1 and VP2 have additional N-terminal
regions. These proteins combine to form the viral capsid. AAV is a non-enveloped virus
with an icosahedral (T=1) capsid of approximately 20 to 30 nm. Capsid structures have been
solved for eight serotypes of AAV: AAV1 [68], AAV2 [69], AAV4 [70], AAV5 [71],
AAV6 [72], AAV7 [73], AAV8 [74], and AAV9 [75]. The three capsid proteins combine to
form the capsid in a ratio of VP1:VP2:VP3 of 1:1:10 [69]; therefore, each capsid contains
fifty copies of VP3 and 5 copies each of VP1 and VP2. The genome is thought to be
packaged into the preassembled capsid in the nucleus [76], through a pore located at the
fivefold axis of symmetry.
Although latent infection with AAV is very common in the human population, no
pathogenesis has ever been linked with AAV [61]. When AAV encounters a host cell, it is
subject to phagocytosis through receptor-mediated endocytosis [77]. The capsid must then
escape from the endosome and be transported to the nucleus, where uncoating occurs [78].
In addition to the common region shared by all three capsid proteins, VP1 and VP2 both
contain nuclear localization signals (NLS) required for the nuclear transport of the capsid
[79, 80]. Furthermore, VP1 contains a phospholipase domain, which is thought to be
required for the endosomal escape of the virion [80]. After the capsid releases the genome,
the genome must then be converted to double stranded form by Rep and cellular DNA
synthesis machinery [81]. As AAV is a non-autonomous virus, it cannot replicate without a
helper-virus functions present in the same cell. In the absence of a helper, AAV DNA can be
retained in circular episomal form [82] or can be integrated into the chromosome at the
AAVS1 integration site [83, 84]. The episomal and integrated DNA are both found in ITR
mediated concatemerized form. In the presence of a helper virus or cellular stress, AAV
transcription and DNA replication are reactivated and AAV completes its replication cycle.
Various helper viruses have been identified for AAV including Adenovirus [63], Herpes
Simplex Virus [85], Vaccinia virus [86], and Human Papillomavirus [87, 88]. In addition,
several chemicals, such as hydroxyurea [89] and carcinogens, such as UV light in the
presence of SV40 T antigen [90], can take the place of a helper virus in allowing productive
replication of AAV. The helper virus is necessary for and increases the efficiency of several
essential functions of AAV. Helper viruses can facilitate nuclear transport of AAV [91],
double stranded DNA formation [81, 92], and the conversion to circular DNA [93, 94].
Helper viruses also activate AAV transcription by releasing the p5 promoter from Rep
mediated repression [95-97]. Furthermore, the helper viruses increase the splicing [98],
transport [99], stability [100], and translation [100] of AAV mRNAs. Finally, the helper
virus facilitates the replication of the AAV genome [101-103] and cell escape [104]. Thus,
an active infection involves helper viral or chemical components in addition to the AAV
viral machinery.
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1.4. AAV as a Gene Therapy Vector
AAV is readily adaptable as a gene therapy vector. In order to use AAV to deliver genes, the
transgene is substituted for the coding sequence for both AAV genes and placed between the
ITRs. The ITRs are the only element of the AAV genome required in cis for packaging and
viral assembly [105]. When producing rAAV, the viral genes and Adenovirus genes
providing helper functions to AAV are supplied in trans to allow for production of the
rAAV particles. In this way, rAAV is produced through a three-plasmid system, decreasing
the probability of production of wildtype virus [106]. Additionally, genomes containing
AAV2 ITRs can be transencapsidated into capsids of various serotypes, which have
differing receptor binding and intracellular trafficking properties [62]. This allows for the
production of AAV with widely varying tropism. Furthermore, self complementary rAAV
genomes (scAAV) are available with a mutated ITR that Rep cannot nick, facilitating the
packaging of a double stranded genome [107]. scAAV avoids the rate-limiting step of
conversion of the single stranded genome to a double stranded, transcriptional active form
and increases transcription kinetics [108]. Because of the flexibility of rAAV vectors, AAV
represents a promising and versatile viral vector for gene therapy.
rAAV is generally thought to navigate the same intracellular trafficking pathway as wildtype
AAV; however, rAAV presents a different genome integration pattern than wild type AAV
due to the lack of Rep. As integration at AAVS1 is specific and dependent on Rep, rAAV
forms episomes or integrates at low frequency at sites throughout the human genome [109].
Most of the integrated DNA, as well as the episomal DNA, is present in the form of head to
tail concatemers, similar to wildtype AAV genomes [110]. Integration events seem to
involve recombination between the ITRs and the host DNA leading to integration of the
rAAV genome and a small deletion of host DNA [111]. Although this integration can occur
throughout the host genome, CpG islands and ribosomal DNA repeats seem to be common
sites of integration [111]. Although a insertional mutagenesis is a possible negative
consequence of integration, the integration of the rAAV genome may allow for long-term
persistence of transgene expression, even in a dividing cell, emphasizing AAV's promise as
a gene delivery vector for gene therapy.
2. CLINICAL TRIALS UTILIZING AAV VECTORS
Due to rAAV's advantageous properties for in vivo gene delivery, approximately seventy
clinical trials using rAAV as a gene delivery vector are currently open, have been
completed, or are under review. Statistics surrounding these trials are summarized in Fig.
(1). The clinical trials utilizing rAAV were reviewed several years ago [60]. The earliest
clinical trials were conducted with rAAV2 vectors to treat cystic fibrosis and hemophilia B.
Lately the number of diseases being tested for treatment utilizing AAV has greatly expanded
and the newest clinical trials are utilizing serotypes other than AAV2. Here we discuss the
history of clinical trials using rAAV for gene therapy and the advantages and problems with
current AAV vectors elucidated by these trials.
2.1. Early Trials with rAAV2
a) Cystic Fibrosis—Thus far, nine clinical trials have been conducted using rAAV2 to
treat cystic fibrosis, a monogenetic disease in which the cystic fibrosis transmembrane
conductance regulator (CFTR) gene is mutated causing intestinal and airway difficulties
(wiley.co.uk/genetherapy/clinical). All of these trials, of which seven are closed and two
remain open, were conducted in the USA. Four phase I, three phase I/II, and three phase II
trials have been performed in this area. These trials can be generally grouped into attempts
to deliver the CFTR gene to the maxillary sinus and relieve chronic sinusitis and attempts to
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deliver the CFTR gene to the lung to allow thinning of the mucus and increased ease in
breathing.
Several clinical trials have focused on transducing the epithelium of the maxillary sinus with
the CFTR gene in an effort to relieve the persistent sinusitis associated with cystic fibrosis.
The first of these trials was a phase I trial in which ten patients were treated with rAAV2-
CFTR in the sinuses. In this trial, no adverse effects were reported and dose-dependent
transfer of the CFTR gene was observed, but there was no long-term effect of the treatment
[112]. In a follow up phase II trial to assess the efficacy of treatment, the vector also caused
no adverse effects; however, no efficacy of treatment was observed [113]. Further studies
have not focused specifically on the sinuses, but instead focused on the lungs or on the
airways in general.
The first trial to use rAAV as a gene therapy vector attempted to use rAAV2 to transduce the
lungs with the CFTR gene in cystic fibrosis patients [114]. In this trial, no adverse effects
were reported for rAAV2 but the treatment failed to demonstrate efficacy. In addition, a
neutralizing antibody response developed to the AAV2 capsid, suggesting that re-
administration of vector might be problematic. In a separate trial, twelve patients were
treated with no adverse effects. However, although the transgene was present throughout the
lungs, no CFTR mRNA could be detected, suggesting a barrier to successful transduction
[115]. Later in a larger trial of forty-two patients utilizing three doses of vector, an increase
in interleukin-8 (IL-8) production and forced expiratory volume (FEV) suggested that this
treatment protocol could lead to increased lung function for cystic fibrosis patients, although
a neutralizing antibody response was developed [116]. However, a follow up study with
approximately one hundred patients failed to demonstrate efficacy, even though the
treatment was well tolerated and safe [117]. Overall, the early clinical trials utilizing rAAV2
to treat cystic fibrosis demonstrated the safety of rAAV mediated therapy, but suggested
difficulty with the transduction of the epithelium with rAAV2.
b) Hemophilia B—To date, three phase I clinical trials have been conducted in the USA
for the treatment of hemophilia B (F.IX deficiency) with rAAV2 mediated gene therapy.
Although hemophilia is caused by the deficiency of a blood protein, the clinical trials
conducted thus far have attempted to transduce either the muscle or the liver in order to
facilitate the production of this protein. The first report on a hemophilia clinical trial with
rAAV2 was a technical report on a trial with three patients conducted by Avigen, Inc [118].
This trial demonstrated that the treatment was safe and there was no evidence of germline
transduction by the vector. In addition, there was a small response by two of the patients,
even with the low dose of vector used. A further study, determined that, after hepatic artery
injection of vector, the vector was transiently observed in the semen; however, this was not
deemed a significant safety concern, as the vector was only present for a short period of time
[119]. A phase I/II, dose escalation trial with seven patients, demonstrated that treatment
was safe with little to no toxicity; however, although effective therapeutic levels of F.IX
were developed with the highest dose of vector, these levels returned to baseline by eight
weeks after treatment due to a cell-mediated immune response [120]. Overall, these trials
demonstrate promising therapeutic value that is limited by immune responses, which were
not predicted by animal model studies [121].
Other studies have examined the possibility of transducing the skeletal muscle through
intramuscular (i.m.) injection of rAAV2 in order to produce F.IX. An early report with three
patients determined that treatment was safe with no evidence for antibody production to
F.IX or of transmission of the vector; however, this study also observed no evidence of
successful transduction or of changes in the serum levels of F.IX [122]. A latter report
confirmed through muscle biopsies that the transgene was expressed, although serum levels
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of F.IX only increased by <1% to2% [123]. This suggests that the treatment may have
efficacy but that higher levels of vector introduced to a greater area of muscle is needed for
successful treatment. In a follow up study, it was determined that this expression lasted for
at least ten months, with a biopsy from one patient maintaining expression after almost four
years [124]. This was the first evidence of successful, long-term expression of a transgene
delivered by rAAV in humans. Overall, the trials with hemophilia and AAV2 suggest that
clinical long-term transduction is possible, but greatly depends on the route of delivery and
immune response.
2.2. More Recent Trials with rAAV2
Since the early trials with rAAV2, many clinical trials have been conducted with rAAV2 to
treat different diseases. One disease that has received a great deal of attention is Leber
Congenital Amerosis type 2, a disease caused by a deficiency in the RPE65 gene, which is
involved in the retinoid cycle. This deficiency causes degenerating vision and eventually
leads to blindness. The clinical trials conducted to treat this disease with rAAV mediated
gene therapy are reviewed elsewhere in this issue.
a) CNS Delivery—Many rAAV gene therapy clinical trials have been conducted to treat
diseases of the central nervous system (CNS) including Canavan disease, Parkinson's
disease, Alzheimer's disease, amyotrophic lateral sclerosis, choroderaemia, and epilepsy. In
all, twelve trials have been conducted for CNS disease of which two trials are closed while
eight remain open (wiley.co.uk/genetherapy/clinical). Six of these trials are phase I, one is
phase I/II, and five are phase II; the majority of the trials were conducted in the USA,
although one was conducted in Sweden and one in Spain. The first use of viral vector
mediated gene therapy for a neurodegenerative disorder was in a trial utilizing a rAAV2
vector to treat Canavan disease [125]. Canavan disease involves a defect in the
aspartpoacylase gene leading to demyelination of neurons and spongiform degradation. In
this trial, ten patients were treated with intracranial injections of the vector and no adverse
effects or immune responses in the CNS were reported, although some systemic antibody
responses were observed. This trial did not assess the efficacy of treatment, but the results
were promising for the safety of rAAV delivery to the CNS.
Seven trials have been conducted to treat Parkinson's disease using rAAV2-mediated
transfer of several different transgenes [126]. The first trial with published results introduced
the glutamic acid decarboxylase (GAD) gene, responsible for synthesizing the inhibitory
neurotransmitter GABA [127]. This phase I trial treated twelve patients with no adverse
effects and observed significant improvements in function through one year after treatment.
A phase II trial is now being conducted with the same vector to assess further the efficacy
and safety of this treatment. In addition, one phase I trial was conducted and three phase II
trials are being conducted with the CERE-120 vector, which is a rAAV2 vector carrying the
neurturin gene, a neurotrophic factor. The results of the phase I trial have been published
and demonstrate the safety of the treatment and some significant improvements in
neurological function [128]. Results have not yet been published from the phase II trials. In
addition, one phase I/II and one phase II trials have used the same vector to treat Alzheimer's
disease. One further clinical trial is being conducted using a different neurotrophic factor,
glial cell line-derived neurotrophic factor (GDNF), but results for this trial have not yet been
reported.
Two further trials have been conducted to treat neurological disorders. The first treats late
infantile neuronal ceroid lipofuscinosis, a lysosomal storage disease that leads to
neurodegeneration, with rAAV2 carrying a functional copy of the defective gene. The
second trial attempts to treat temporal lobe epilepsy with the introduction of a rAAV2 vector
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containing the neuropeptide Y gene to the hippocampus. Overall, the use of rAAV2 for gene
delivery in the CNS holds great promise due to its safety and the long-term effects observed
in this immunoprivileged site.
b) Other Trials—Many trials have also been conducted using rAAV2 to study other gene
therapy applications. Two phase I clinical trials are being conducted in the USA to treat
alpha-1 anti-trypsin (AAT) deficiency, which can lead to lung and liver damage due to
decreased inactivation of trypsin. One of these trials utilized AAV2 and the results of this
trial have been published [129]. This dose escalation trial, involving twelve patients,
delivered the vector through i.m. injection and determined that the treatment was safe,
although anti-vector antibodies were developed. The level of transgene expression was not
determined. Furthermore, three phase I clinical trials have been conducted in the USA and
Canada to treat inflammatory arthritis, such as rheumatoid arthritis (wiley.co.uk/
genetherapy/clinical). Two of these trials are closed and one is open. A published trial
introduced a rAAV2 vector containing a TNF-α antagonist to the joint of fifteen patients
through intra-articular injection [130]. Although the treatment was determined to be safe and
well tolerated, the dose used was too low to determine if the treatment was efficacious.
A number of trials for other disease have also been initiated, although no results have yet
been published. Sixteen trials have been conducted to evaluate the use of rAAV2 mediated
gene therapy to treat cancer (wiley.co.uk/genetherapy/clinical). The majority of these trials
are intended for metastatic hormone-refractive prostate cancer, although one phase I trial has
been initiated to treat melanoma and another has been initiated to treat Epstein-Barr virus
positive carcinoma. Seven of the prostate cancer trials, in the USA, UK, and Netherlands,
are phase III trials. In addition to the many trials treating cancer, two trials are ongoing to
evaluate the use of rAAV2 as a vector for gene therapy to treat heart failure and three trials
have been conducted to use rAAV2 as a gene therapy vector to treat forms of muscular
dystrophy including limb-girdle muscular dystrophy and Duchenne muscular dystrophy.
Overall, these trials demonstrate the versatility of rAAV2 as a gene delivery vector;
however, problems with pre-existing immunity, tropism, and loss of transgene expression
have lead researchers to explore the use of other serotypes of AAV.
2.3. Newer Trials with Other Serotypes of AAV
Several trials have now been conducted that utilize the capsids of AAV serotypes other than
AAV2 including AAV1, AAV6, AAV8, and AAVrh.10, as well as an engineered serotype,
AAV2.5. All of these trials utilize a genome with AAV2 ITRs transencapsidated into the
capsid of another serotype. The most trials have been conducted with rAAV2/1, which has
greater tropism for muscle than AAV2. A phase I trial to treat AAT deficiency with a
rAAV2/1 vector containing the AAT gene determined that i.m. injection of the vector was
safe and was not related to any adverse effects [131]. Furthermore, although neutralizing
antibody and cell-mediated immune responses were developed to the vector the expression
of the AAT transgene was maintained for at least one year.
Trials have also been conducted for forms of muscular dystrophy using rAAV2/1 vectors. In
a trial to treat limb-girdle muscular dystrophy, a rAAV2/1 vector was used to introduce the
alpha-sarcoglycan gene through i.m. injection with a concurrent three-day course of
methylpredisolone immunosuppression [132]. This treatment resulted in a capsid specific
antibody response but very little cell-mediate immune response. In addition, increases in
muscle fiber density, along with four to five fold increases in alpha-sarcoglycan levels, were
observed at three months after treatment, demonstrating the promising nature of the
treatment, despite the early time point. An additional phase I/II clinical trial is designed to
treat Pompe disease, a glycogen storage disease leading to loss of muscle function, by
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delivery of a rAAV2/1 vector carrying the acid alpha-glycosidase gene to the diaphragm
(wiley.co.uk/genetherapy/clinical). Results have not yet been published for this trial.
Furthermore, a phase I/II trial is also being conducted to treat lipoprotein lipase deficiency, a
disease that leads to high serum triglyceride levels and pancreatitis. In this dose escalation
trial, a rAAV2/1 vector carrying the lipoprotein lipase gene is delivered by i.m. injection.
The highest dose of vector led to a 41% decrease in serum triglyceride levels; however,
these levels returned to baseline by eighteen to thirty months after treatment [133].
Moreover, anti-capsid antibody and T cell immune responses were developed and, in at least
one case, lead to cytotoxicity and transgene loss [134]. No anti-transgene immune responses
were detected. One final rAAV2/1 trial introduces the vector containing the SERCA2a gene
through intracoronary injection to treat heart failure. SERCA2a, or sarcoplasmic reticulum
Ca2+ ATPase, is involved in calcium signaling regulation in cardiomyocytes and reduction
in its function has been linked with heart failure [135]. Results of this trial have not yet been
published.
Clinical trials have also been initiated with other serotypes of AAV, although no results have
yet been published from these trials (wiley.co.uk/genetherapy/clinical). As AAV6 is much
more efficient at transducing human airway epithelium cultures than other AAV serotypes
[136], a phase I trial is currently examining its use to deliver the human placental alkaline
phosphatase gene to the upper airway of cystic fibrosis patients in order to determine the
efficacy of the rAAV2/6 vectors. In addition, one currently open trial and one trial with
conditional approval are using self-complementary rAAV8 (scAAV2/8) to deliver the F.IX
gene to the muscle to treat hemophilia. As AAV8 has strong expression in the muscle [137],
enhanced by the self-complementary genome [108], this vector should allow for high levels
of F.IX to be produced. Furthermore, AAV8 capsids tend to elicit high numbers of
regulatory T cells, which may lead to longer-term transgene expression [138]. Another
clinical trial, currently under review, will attempt to treat late infantile neuronal ceroid
lipofuscinosis with CNS delivery of a simian serotype of AAV, AAVRrh.10. rAAVrh.10
demonstrated the highest expression levels, local spread, and clinical improvement of
several AAV serotypes in pre-clinical mouse model studies [139]. One final clinical trial, for
the treatment of Duchenne muscular dystrophy, utilizes a non-natural serotype of AAV
known as AAV2.5, which incorporates capsid proteins with regions from more than one
serotype of AAV. The recent trials using various serotypes of AAV demonstrate the
versatility and adaptability of rAAV vectors.
2.4. Clinical and Biological Issues with Current rAAV Vectors
The many clinical trials utilizing rAAV vectors have demonstrated the safety and versatility
of rAAV for gene delivery. However, although the recent trials with serotypes of AAV other
than AAV2 have circumvented some issues with early clinical trials, some difficulties with
current serotypes remain. Several trials have demonstrated that transgene expression is not
maintained long-term in humans in nonimmunoprivileged sites [117, 123]. In addition, a few
trials have suggested the possibility of vector dissemination at early time points after
treatment [120]. Furthermore, it is possible that, if a transduced cell carried a wildtype AAV
genome and was super-infected with a helper virus, the vector genome could be mobilized
and disseminated. Transgene expression can also be inhibited by both pre-existing immunity
to the AAV capsid [140] and by development of capsid specific immune responses to the
vector [117, 123]. The anti-capsid immune response also posses issues for re-administration
of the vector. Moreover, a risk of insertional mutagenesis due to rAAV mediated gene
therapy exists [111]. Some applications are also prevented by the limited packaging capacity
of AAV. However, work with newer natural serotypes and with the design of non-natural
capsids is leading to vectors that avoid many of these problems. The strategies being used to
create these vectors are discussed below.
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3. CAPSID DESIGN TO IMPROVE PERFORMANCE IN A CLINICAL SETTING
A fundamental requirement of gene therapy is the ability to target specific tissues for
therapeutic gene delivery and, equally importantly, to detarget those tissues that are
unnecessary for correction of a given genetic disease. Production of an efficient targeted
delivery system overcomes several limitations, including deleterious effects arising from the
introduction of genetic material into the incorrect cell type, large therapeutic doses, and
inefficient transduction of the tissue or cell type being targeted. To attempt to produce a
targeted virus, extensive research has been performed on both the biology of individual
natural serotypes as well as the construction of laboratory-derived serotypes that maximize
gene delivery to intended tissue while avoiding sequestration in non-targeted tissue types.
As increasing numbers of naturally occurring serotypes from different primate and other
animal species have been discovered [141-146] (reviewed in [147]), the known diversity of
AAV's tropism has broadened [137, 148-152]. This has important implications for the
design of a targeted vector, as taking advantage of and enhancing the naturally ability of the
virs has distinct advantages over de novo development of novel serotypes. The ability to
transencapsidate AAV [153, 154] allows for a true comparison of capsid effects of targeting
and transduction while avoiding any potential changes caused by the genome variation.
3.1. Rational Design of the AAV Capsid based on Structural Analysis
The emergence of several AAV serotypes’ crystal and cryo-EM structures [68-71, 73-75,
155] as well as the co-crystal structure of AAV2 bound to its cognate heparin sul-fate
proteoglycan receptor [156] has opened the door to rational design of the capsid based on its
topological features. One of the most notable impacts these structures have had on rational
design is the identity of regions of the AAV2 capsid that are involved in binding to heparin
sulfate have been confirmed [157]. Indeed, in recent times researchers have become
increasingly aware that this binding site on the capsid needs to be ablated in order to change
AAV2 targeting [158-161]. However, the availability of the crystal structures has done more
than confirm previous ideas: it has allowed researchers to begin devising specific plans for
improving AAV2 targeting as well as transduction. To date, rational design of the capsid has
been employed to improve targeting [162], gene expression [163, 164] and viral production
[165]. Recent advances in rational design are discussed below.
The ability to use the AAV2/heparin sulfate co-crystal to design novel vectors is exemplified
by a 2010 study by Asokan et al. in which the negatively charged patch comprising residues
585-590 of the AAV2 capsid – a surface loop known for its interaction with heparin sulfate
– was swapped with residues 585-590 of AAV8, a vector known for its systemic
transduction profile [137]. These mutations were made based on the alignment of the
receptor footprint of the sero-types. It was hypothesized that the swap would not only ablate
the binding of AAV2 to its natural receptor, thereby potentially detargeting the virus from
the liver, but also confer some of the systemic dissemination properties of AAV8 to the
virus. The new construct was termed AAV2i8 as it contains the AAV2 backbone with the
inner loop of the threefold axis replaced with residues from AAV8. AAV2i8 exhibited a 40-
fold decrease in liver gene expression compared to AAV2 upon IV injection into C57BL/6
mice. Additionally, high expression levels were observed in all types of muscle cells,
including cardiac, skeletal, facial, and diaphragm. Furthermore, low levels of expression
were observed in brain, lung and spleen, illustrating that AAV2i8 has a tropism unique from
either of its parental serotypes. While the receptor for this new construct is not known, it is
clear is that there is sequestration in tissues other than the liver through heparin-sulfate
independent uptake. One potential explanation for at least part of this new vector's
widespread muscle transduction is that it exhibited markedly reduced blood clearance—
persisting for well over 48 hours in circulation [162].
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Creation of better vectors through rational design of the capsid has not been limited to
improving tissue targeting abilities; in 2008 a series of papers were published illustrating
that site-directed mutagenesis of the capsid can also be used to improve transduction
efficiency [163, 164]. It had been previously established that EGFR-PTK phosphorylation of
tyrosines in the viral capsid proteins negatively affects transduction levels, targeting the
capsid for proteasomal degradation and thereby preventing nuclear localization of the vector
[166, 167]. Zhong et al. hypothesized that mutating each of the tyrosines that undergo
phosphorylation to phospho-deficient phenylalanine would improve transduction by
allowing the virus to escape degradation. The crystal structure of AAV2 was used to map
solvent-exposed tyrosines on the capsid surface and 7 residues were chosen for mutation. It
was determined that mutants Y444F and Y730F had the greatest impact on transduction
efficiency, with up to a 29-fold gene expression increase observed in mouse hepatocytes
after IV administration of these vectors to C57BL/6 mice. Furthermore, when the human
Factor IX (hF.IX) gene was packaged in AAV2/Y730F vector, it was demonstrated that a
10-fold reduced therapeutic vector dose produced the same transduction levels as wild-type
AAV2 [164]. Similar results were observed by Petrs-Silva et al., who used tyrosine to
phenylalanine mutations at structurally equivalent positions on the capsids of AAV2, AAV8,
and AAV9 to examine changes in transduction efficiency upon intravitreal delivery of
vector to the retina. A 20-fold increase in transduction of retinal cells was demonstrated for
AAV2Y444F versus wild-type; additionally, many more cell types comprising the retinal
ganglionic layer showed reporter gene expression that with wildtype virus. It should be
noted that the tropism of these viruses had not been altered, but rather that transduction was
enhanced with these mutations so that gene expression became measurable in additional
retinal cell types. Fur thermore, none of these mutations conferred any negative impact to
capsid stability or titer [163].
3.2. Insertion of Targeting Ligands onto the AAV Capsid to Control Vector Tropism
The insertion of targeting peptides onto the capsid surface in an effort to direct the virus to
refractive cell types has been widely explored. To date, targeting peptides have enabled or
enhanced transduction in muscle [168], lung [169, 170], circulatory vasculature [171],
atherosclerotic lesions [172], hematopoietic progenitor cells [173, 174], vascular endothelial
cells [175-177], pancreatic islet cells [178], various tumor lines [158, 160, 161, 179, 180],
and leukemia cell lines [173, 174], among others. Two major areas of research have been
utilized in these efforts: 1.) determination of capsid regions that will tolerate peptide
insertions while maintaining an intact capsid and high-titer virus, and 2.) determination of
targeting peptides to use in order to effectively direct the virus to a given cell type. When
designing a virus to include targeting peptides for a cell-type specific receptor, a number of
considerations must be accounted for. First, the peptide conformation and biological activity
may be altered, attenuated, or completely ablated when placed in the context of the viral
protein. Indeed, a given insertion site may not render a peptide solvent-accessible .
Secondly, peptides need to be selected not only for cell-type specific receptors but also for
internalization into the cell so that AAV can deliver its genetic material. With the relatively
limited knowledge of the receptorome of any given cell type this is not a trivial undertaking.
Finally, the peptide insertion cannot deleteriously affect other aspects of the viral life cycle,
including monomer association and capsid formation, genome packaging, intracellular
trafficking, and viral uncoating to deliver DNA. A number of strategies that have been in
employed to address these considerations are discussed below.
The original investigation into incorporating targeting peptides onto the virus focused on
using phage-display identified or already known peptides that interact with specifically
chosen receptors for insertion onto amenable regions of the capsid . Widespread insertion
point analyses of the capsid using such peptides has been performed [79, 158-161, 179,
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181-184]. While some successes have been and continue to be apparent in pre-meditated
choice of targeting peptides, a limitation of this approach is that it only optimizes receptor
targeting and not other fundamental aspects of the viral life cycle. Additionally, the receptor
being targeted may only exist at low levels on a given cell type. To overcome these
limitations, approaches focusing on directed evolution of peptide ligands contained on the
capsid surface for transduction of a given cell type have been developed. These approaches
ensure that the virus can not only bind to a receptor, but also can complete internalization
and genome delivery in the context of the inserted ligand.
A combinatorial, high-throughput approach is taken when performing directed evolution of
targeting ligands in the context of the capsid [173-175, 179, 185-187]. Generally, a library is
generated containing capsid-modified viral particles carrying random insertions of amino
acids at a defined position. Common positions for these insertions are at residues 587 or 588
on the AAV2 capsid, as insertions in this region will disrupt the heparin-binding region of
the capsid so that competition with heparin sulfate proteoglycan recognition is ablated. If
using a position other than this for peptide insertion, site-directed mutagenesis of select
residues within the capsid's heparin sulfate recognition region can improve targeting
capacity [183]. The library of capsid mutants is then allowed to infect a given cell type in
vitro and the viral progeny created in this cell type are harvested. This process is repeated
iteratively until very few clones remain, in a strategy known as biopanning. The selective
pressure provided by only choosing progeny that have been able to not only replicate within
but also re-infect a given cell line ensures that the viral clones can accomplish each step in
the viral life cycle successfully.
Recently, in vivo biopanning has been explored to enhance the selection process, as AAV
particles do not need simply to be able to bind to a cell receptor, but need to achieve this
interaction under circulation conditions. Additionally, they need to evade the host immune
response, as well as overcome a variety of physical barriers while locating their target tissue
type. In a combination in vitro and in vivo biopanning study, peptide-bearing viruses were
subject to selection on breast and lung tumor tissue in vitro. These viruses were then
subjected to a second round of selection in tumor bearing mice. While orders of magnitude
increases in transduction of tumor tissue were observed in vivo, a surprising artifact of this
study was the enhanced transduction of heart tissue in nearly all isolated vectors. This
illustrates that subjecting vectors to in vivo selection is becoming fundamentally important
both in the design of clinically relevant therapeutics, as well as in enhancing our
understanding of AAV biology on a macroscopic scale [188].
4. RANDOM MUTAGENESIS DESIGN OF ADENO-ASSOCIATED VIRAL
VECTORS
While ligands and peptide insertions provide a way to directly target specific cell receptors
and might facilitate more efficient post-entry trafficking steps, these capsid additions have
several limitations. First, the insertion is limited to locations on the capsid that will not
negatively impact receptor-mediated entry or subsequent transduction. Therefore, rational
design of peptide insertions requires pre-existing knowledge of capsid sites that are tolerant
for insertions. Second, the specificity of many peptides or ligands depends on their
conformation, so a simple insertion that does not achieve the correct three dimensional
structure may be ineffective at its desired function. Third, a modified capsid may still be
subject to neutralization by pre-existing anti-capsid antibodies. More recent strategies in
capsid design, including engineering novel vectors that utilize the natural diversity of newly
discovered serotypes, are being explored to achieve the same goals of non-natural capsid
design: enhanced transduction, specific tropism, and immune evasion. These approaches
include the creation of mosaic and chimeric capsids.
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4.1. Mosaic Adeno-Associated Viral Vectors
Mosaic capsid engineering allows for the creation of hybrid vectors that are heterogeneous
at the protein level, i.e. the capsid proteins from more than one serotype of AAV are
combined to compose a novel capsid particle Fig. (2A). In these production systems,
plasmids encoding different viral proteins are added in a ratio that achieves the desired
proportion of each viral protein within each capsid. In all of the reports using mosaic
vectors, a certain ratio of viral proteins from two serotypes achieved additive effects in
transduction. In the first report highlighting the utility of mosaic capsids, Hauck et al.
engineered a vector consisting of AAV1 and AAV2 at a 50:50 ratio which achieved a
several fold greater transduction in the liver and spleen as compared to the parent serotypes
alone [189]. Furthermore, Rabinowitz et al. engineered mosaic viruses from combinations of
AAV1-AAV5. Whereas AAV2 only binds to heparin and AAV5 only binds to mucin, the
AAV3/5 (3:1) mosaic was able to bind to both mucin and heparin. Combining AAV1 with
AAV2 and AAV1 with AAV3 allowed for enhanced transduction of some cell types over
any parent serotype alone. Some changes in transduction were either abrupt or incremental
depending on the composition of the mosaic capsid and the cell type [153].
Additionally, the use of mosaic viruses that contain part wild type viral proteins and part
viral proteins with targeting ligand insertions restores the transduction capabilities that are
often hampered when targeting ligands are on all of the monomers in the capsid. Efforts
have been made to engineer a viral capsid with an ideal ratio of viral proteins with desired
targeting properties along with transduction capabilities. For example, Gigout et al. created
AAV2 mosaic capsids containing 25% capsid protein with an IgG binding fragment that, by
adding an antibody, could be directed to cell targets while maintaining high levels of
transduction. The success of these results is highlighted by the fact that a capsid composed
of 100% IgG containing viral particles yielded no transduction [190]. Moreover, the
vasculature integrin targeting peptide RGD4C coupled with biotinylated viral proteins in a
90/10 ratio yielded vectors capable of efficient transduction of HeLa and HUVEC cells that
could also be highly purified using avadin affinity chromatography [191].
The onset of mosaic vector engineering demonstrated for the first time ways to combine
useful capsid components from more than one serotype to create an optimized vector with
desired traits. However, because these vectors still consist of viral proteins from natural
serotypes, they are likely to be subject to any preexisting immunity for the parent serotype.
4.2.1 Directed Evolution Strategies for Adeno-Associated Vectors: In Vitro
Selection—The natural course of AAV evolution has yielded serotypes with varying tissue
tropism, antibody recognition, trafficking, replication, and gene transfer. Of course,
naturally evolving viruses have been generated over a long period of time and with selective
pressure from environmental factors. A rapidly developing strategy, known as directed
evolution, exploits the natural course of evolution and serotype diversity through the
creation of either chimeric or randomly mutated capsids. By applying recurrent rounds of
selective pressure, an “evolved” chimera emerges exhibiting desirable traits rendering
fitness for the given criteria. An example chimeric capsid is illustrated in Fig. (2B).
The first example of the directed evolution strategy was pioneered by Maheshri et al., where
error-prone and staggered extension PCR was performed on AAV2 cap to produce a library
of mutants. A selective pressure of a pre-incubation with rabbit anti-AAV2 serum followed
by transduction and replication in 293T cells was used. The resultant clones exhibited a
diverse range of heparin binding, unlike AAV2 which has high affinity for heparin. The
group determined that the variants could evade neutralizing antibodies, thought to be due to
an alanine mutation on the C-terminus of VP3 observed in all of the variants. Furthermore,
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these variants could successfully deliver erythropoietin to mice even after opsonization with
antiserum [192].
Li et al. and Koerber et al. expanded on this approach by using the DNA shuffling
techniques developed by Stemmer [193, 194]. This approach involves fragmenting the cap
genes of multiple AAV serotypes, reannealing the fragments in a primerless PCR reaction,
and creating full length chimeric cap genes in a second PCR reaction. Chimeric viral
libraries were generated comprised of the chimeric shell encapsidating the corresponding
cap gene and AAV2 rep gene [195]. This group evolved a chimeric variant (AAV1829) that
could transduce several melanoma cell lines and evade AAV2 neutralizing antibodies by
shuffling the cap genes from AAV1-9 and selecting on Chinese hamster ovary cells.
AAV1829 was also de-targeted from the liver when administered systemically and
demonstrated less muscle transduction (after hind limb injection) than any of its parent sero-
types [195]. Using a similar approach, Koerber et al. observed that chimeric capsids display
a wide range of cell-type tropisms and sensitivity to neutralizing antibodies [196].
These initial studies demonstrated the utility of chimeras and created the platform for using
high throughput selection approaches to evolve new AAVs with desired properties. For
example, AAV-mediated therapy for cystic fibrosis has been hindered by limited gene
transfer to airway epithelium. By shuffling AAV2 and AAV5 cap genes, Excoffon et al.
were able to evolve a single chimera (AAV2.5T) from separate selections on different
primary human airway epithelial cultures. This clone demonstrated significantly higher
apical airway transduction compared to either parent which led to phenotypic correction of
cystic fibrosis epithelia [197]. Two variants from an AAV1-9 library selected on human
airway epithelial cultures (HAE-1 and HAE-2) could also transduce human cystic fibrosis
airway epithelia and deliver the CFTR gene. Furthermore, this study demonstrated that the
use of pharmacological agents could enhance transduction (see below: Future Directions)
[198]. Using a combination of libraries produced by random mutagenesis, peptide display,
and shuffling of AAV1-9, Koerber et al. evolved several variants with enhanced astrocyte
tropism in vivo and one clone with enhanced Müller glia transduction over parent serotypes
[199].
Shuffled viral libraries are rapidly expanding in diversity to include AAV serotypes not
found in the human population in addition to well characterized serotypes. Grimm et al.
created a shuffled library composed of avian, goat, and bovine AAV cap sequences in
addition to AAV2, AAV4, AAV5, AAV8, and AAV9 cap sequences. This group evolved a
virus (AAV-DJ) through selection on a liver hepatoma cell line with the additional pressure
of pre-incubation in pooled human antisera. AAV-DJ demonstrated efficient transduction of
several cell types over parent serotypes and was able to confer long-term hF.IX expression
similar to AAV8 and AAV9 [170]. In addition, Rhesus macaque serotypes AAVrh.8 and
AAVrh.10, along with AAV1, AAV2, AAV5, and AAV9 cap sequences were used to create
a shuffled library that contained an evolved vector (AAV-U87R7-C5) with enhanced
transduction capabilities for several glioma cell lines and human brain tumor stem cell
neuro-spheres [200].
4.2.2. Directed Evolution Strategies for Adeno-Associated Vectors: In Vivo
Selection—Two groups have extended the in vitro efforts of directed evolution to a more
physiologically relevant setting by using in vivo biopanning. The directed evolution
approach in an in vivo setting removes any bias associated with cultured cells and produces
variants with properties that more closely achieve therapeutic goals for whole tissues and
organs. This process involves systemic administration of a chimeric viral library, resection
of the target tissue, and PCR amplification of the sequestered vector genomes, which are
then used in the next iterative cycle of selection. Using an AAV1-9 shuffled library, Yang et
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al. evolved a heart-tropic vector (AAVM41) with similar transduction levels as AAV9 but
enhanced tropism (and detargeting from other tissue types) after systemic delivery.
Furthermore, AAVM41 successfully mediated gene transfer of δ-sarcoglycan to TO-2
hamsters, resulting in restoration of normal cardiac morphology and improved cardiac
function [201]. Using a combined technique of compromising the blood brain barrier (BBB)
with Kanic acid-induced seizure followed by the application of an AAV1-9 shuffled library,
Gray et al. evolved a vector (clone83) that could efficiently transduce neurons and
oligodendrocytes while being de-targeted from the liver and most other organs when
administered systemically [202].
Currently, directed evolution is the fastest way to create novel AAV vectors that display
enhanced tropism for specific cell types, are de-targeted from undesirable cell types, and
achieve efficient transduction. Efforts have been made to enhance this approach, and
developments will continue to yield improvements in vector design. Semi-random loop
shuffling has been described, along with using combinatorial libraries to create widely
diverse chimeras [197]. One caveat to the biopanning approaches is that results in cell lines
and animal model may not be directly comparable to results in humans. Nevertheless, in
vivo biopanning should continue to be explored, as directed evolution in an in vivo setting
could yield AAV variants that are tumor-tropic or achieve efficient transduction in specific
cell subsets. Efforts are ongoing in these areas and will likely lead to significant
contributions in their respective fields.
5. MODIFYING THE CAPSID WITH EXOGENOUS AGENTS
While genetic manipulation of capsid proteins has shown great potential for the creation of
targeted vectors, additional methods of vector design such as introducing exogenous agents
to the viral capsid have been explored with some success. These approaches range from the
use of bi-specific antibodies used to conjoin the virus to a receptor [203], facilitating cell-
type specific uptake, to biotinylation serving as a platform for conjugation targeting ligands
[204-206]. Furthermore, coating the viral capsid in sheathing agents can serve not only to
defy antibody neutralization but to act as derivitization platforms for targeting ligands [207,
208]. A few of the more recent exogenous agent targeting approaches are discussed below.
Carlisle et al. examined the ability to simultaneously retarget the virus and escape immune
detection by coating the viral particle with reactive HPMA copolymers. Subjecting AAV5
and AAV8 to this coating efficiently shielded their natural receptor epitopes and attenuated
natural receptor binding affinities as well as antibody recognition. Additionally, covalently
linking specific targeting ligands to the polymer layer introduced receptor-specific targeting
abilities. The charge profile of the AAV5 capsid interfered with the HPMA linking process
and thus, while HPMA coating was accomplished on this serotype, it was at the expense of
clinically relevant viral yields. AAV8, however, was highly tolerant to HPMA linkage.
Coating of AAV8 in this manner led to significant detargeting of its natural cell targets.
Copolymer pre-derivitized with murine EGF and linked to AAV8 resulted in significantly
increased transduction of COS-7 cells over wild-type AAV8, demonstrating that this method
can creating a novel tropism. Additionally, polymer coating improved AAV8 blood
circulation time, with 3-fold greater plasma levels versus wild-type virus 24 hours post i.v.
injection into C57B16 mice [207].
In an effort to improve or alter in vivo lung tropism, Fein et al. used cationic lipid
formulations to coat two chimeric AAV vectors known for their ability to transduce the
alveolar epithelium [209]. Barriers implicit in the extracellular environment of the
respiratory epithelium create a significant challenge for traditional gene delivery approaches.
Dexamethasone-spermine (DS) and disubstituted spermine (D2S), two cationic sterol-based
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lipid formulations, were used to coat AAV2/9 and AAV2/6.2. An advantage of this strategy
is that the lipid coating is formed through electro-static interaction with the capsid and does
not neccessitate use of sophisticated covalent attachment chemistry. Lipid treatment caused
the formation of 100-1000 virion clusters, which were delivered to cells. Transduction of
A549 cells was increased 7-fold with AAV2/9 D2S treated particles relative to untreated
virus. Following intranasal instillation of C57BL/6 mice, AAV2/6.2 treated with DS was
determined to be the most efficacious combination, exhibiting a 4-fold increase in gene
expression in the alveolar epithelium relative to non-lipid control. Additionally, it was
demonstrated that when AAV2/9 was treated with DS and introduced to the nasal passage
that the conducting airway was efficiently transduced. In the non-lipid AAV2/9 control, only
alveolar epithelium exhibited transgene expression, illustrating a lipid-induced expansion of
the vector's tropism. It is thought that the enhancements and differences in transduction
observed in the lipid-treated virions are due to non-receptor mediated endocytosis of the
lipid structure. If this is the case, then the formation of large clusters of viral particles upon
lipid treatment may increase internalization of complexes containing multiple particles,
increasing transgene copy number in the target cell population.
In a 2008 study, Bartlett et al. devised a strategy to covalently link either fluorophores or
targeting ligands to the capsid without losing titer or causing other deleterious effects to the
viral particle [206]. The goal of this study was to develop a platform that could be
simultaneously used to attach a targeting ligand and/or a fluorphore to the capsid in order to
gain information on how the ligand affects intracellular trafficking. While peptide insertions
have proven to be a useful targeting tool, it is unclear what these genetic modifications of
the capsid may alter other than simple receptor recognition. The development of a strategy
that allows intracellular tracking of the virion to be followed in the presence of a targeting
peptide can provide valuable illumination on potential viral life-cycle changes induced by
the peptide.
To accomplish this, a biotin acceptor peptide (BAP) sequence was genetically inserted into
the AAV1 capsid to serve as a recognition site for the E. coli enzyme BirA, which catalyzes
the biotinylation of a specific lysine residue within the BAP consensus sequence. BirA will
also accept isosteres of biotin in this reaction such as ketone 1, which is not present in
naturally occurring proteins, lipids, and carbohydrates and thus allows for selective
derivitization onto the capsid surface. Additionally, as the reaction is enzymatically
performed, it occurs under physiological conditions so the capsid does not undergo harsh
chemical processes. Covalent linkage of the ketone to the capsid allays any concerns that a
fluorophore or targeting ligand can become detached during trafficking and confound the
data [206].
To create an intracellular monitoring system of AAV, alexa fluor hydrazides were used to
derivatize the ketones. This created a highly sensitive fluorescent labeling system that did
not interfere with the particle's natural receptor utilization or intracellular trafficking. The
system was then tested for the ability to accept conjugation of a synthetic cyclic-RGD
peptide (c(RGDfC)) designed to target integrin receptors. The new vector demonstrated
significantly enhanced transduction of cultured human endothelial cells, specific to the
targeted integrin receptor. Furthermore, in a murine model of peritoneal ovarian cancer, i.v
vector administration resulted in efficient gene transfer to the tumor-associated vasculature
with no significant change in transduction of other key organs, such as the liver, spleen, and
heart. Future efforts with this labeling technology will no doubt examine additional targeting
ligands, as well as potential biophysical probes for monitoring changes in environmental pH
or assaying PLA activity [206].
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6. USING TISSUE-SPECIFIC PROMOTERS FOR AN ADDITIONAL LEVEL OF
TARGETING CONTROL
An additional level of transcriptional targeting can be added to the virion through inclusion
of tissue-specific promoters to drive expression of a given transgene. To develop a vector
construct for treating a variety of genetic eye diseases effecting photoreceptors, Sun et al.
used a promoter derived from the human rhodopsin kinase gene in order to drive the
transgene expression. This promoter is known to be active in both rods and cones, but not in
other regions of the eye, such as the retinal pigment epithelium (RPE). The promoter drove
the expression of the transgene–AIPL1–at near endogenous levels in both types of cell
[210]. While promoter-driven rod or cone-selective gene expression had been achieved
previously [211-213], this represents the first successful example of targeting a transgene to
both types of photoreceptor simultaneously. As expected, no transgene expression was
observed in either the RPE or inner retinal neurons, confirming that the promoter was able to
drive selective tissue expression of the virus [210].
Transcriptional targeting success has not been limited to the eye. The hTERT, the main
component of human telom-erase, is selectively expressed in cancers [214]. As such, the
tumor-specific hTERT promoter can be used to drive gene expression in cancers without
achieving measurable expression activity in normal cells [215, 216]. Using the hTERT
promoter to drive the expression of cell lethal transgenes such as TRAIL and IFN-β
delivered by AAV vectors has demonstrated potent anti-tumor effects in mouse cancer
models while sparing normal cells [217-219]. The promoter of the glucose transporter
isoform 1 (GLUT1) is another cancer-specific transcription element that has been
successfully used to drive selective transgene expression in tumors [220]. In fact, when
combining the GLUT1 promoter with the herpes simplex virus thymidine kinase gene,
treatment with gangciclovir achieved total tumor remission in a subcutaneous rodent model
of hepatoma. These results indicate that combining a selective promoter with the correct
capsid and transgene could create an attractive platform for the potential selective targeting
of human cancers.
The use of tissue-specific promoters is proving to be an effective means of refining AAV
targeting to desired tissue types. It is unlikely that the field will evolve to rely solely on
promoter control of transgene expression as this strategy does not prevent viral sequestration
in undesired cell types, which impacts how much virus is delivered to patient and
necessitates unrealistically high therapeutic doses. The use of selective promoters does,
however, allow refinement of targeting control on the genomic level, which can act in
powerful synergism with targeting efforts on the protein level to improve therapeutic gene
delivery designs [221].
7. STRATEGIES TO AVOID THE IMMUNE RESPONSE
7.1. Immune Response to rAAV
One of the biggest advantages of using AAV as a gene therapy vector over other viral
options is that, traditionally, AAV is thought of as an essentially non-immunogenic virus,
eliciting minimal innate and cellular immunity from the host. The major immune response to
AAV is in the form of neutralizing antibody (NAb) formation to the capsid, which typically
prevents receptor binding and cellular re-entry of AAV upon readministration In addition,
the transgene product can also evoke an immune response, as the therapeutic protein is
sometimes viewed as a “neoantigen” since the host may not recognize the protein as “self”
[222-230].
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The most prevalent AAV serotype in the human population is AAV2, with the first infection
from this virus usually occurring in 30-80% of the human population in early childhood
[231]. This percentage is similar for AAV3 [232], while the seroprevalence of AAV6 is only
about 30% [233]. Less prevalent serotypes include AAV5, which has been determined to
have infected between 10-20% of the population [232-234], while AAV7 and AAV8
infection is only seen at a frequency of about 6% and elicit a minimal neutralizing antibody
response [141]. Around 90% of humans harbor antibodies that react to one or more
serotypes [63, 231, 232, 235-237]. Furthermore, memory T cell populations have been
reported in around 60% of the population [238].
Recent work has mapped the origins of AAV immunity to the activation of the innate
immune system, the host's first line of defense that shapes subsequent adaptive responses
[239]. Zaiss et al. demonstrated that AAV2 interacts with complement component C3 and
regulatory factor H, to allow binding with iC3b, which increases uptake into macrophages.
Activation of the complement cascade occurred primarily through the classical pathway in
vitro and through the alternative pathway in murine studies. In addition, C3 knockout mice
challenged with AAV vectors specifically displayed deficient humoral activity compared to
wild type mice [240]. In another study, Zaiss et al. identified many up regulated innate
signaling molecules, along with recruitment of neutrophils and CD11b+ cells, upon I.V.
administration of AAV2 in mice [241]. Zhu et al. demonstrated that AAV2, and to a lesser
extent AAV1 and AAV9, activate plasmacytoid dendritic cells which though the TLR9/
MyD88 signaling pathway produce IFNα and IFNβ. This signaling induced the activation of
AAV-specific T cells which corresponded to a loss in transgene expression along with
antibodies against the transgene and capsid [242].
Emerging data has identified antibody epitopes in humans and mice that elicit the humoral
immune response [243, 244] and CD4+ and CD8+ T cell epitopes in humans and mice that
elicit a cellular immune response [238, 245-247]. Human antibodies to AAV are primarily
IgG1 and IgG2 but all IgG subclasses can be detected [248, 249]. Currently known AAV
epitopes are illustrated in Fig. (2C). Furthermore, as AAV gene therapy advances to the
clinical setting, it is coming to light that pre-clinical animal models may not be completely
indicative of the immune response elicited in humans. NAb formation to rAAV has been
documented in several clinical trials (see clinical trials section). Cell-mediated responses
have also been reported. One of the first clinical trials sought to achieve long term
therapeutic levels of human factor IX (hF.IX) through intrahepatic artery administration of
AAV2 carrying the hF.IX transgene. Therapeutic hF.IX levels were transiently achieved in
one subject in accordance with a rise and fall in liver transaminases [120] . These events
were later determined to correspond to an expansion and contraction of CD8+ T cells
specific for the AAV2 capsid along with the development of effector memory CD8+ T cells
[238]. These results led the authors to propose that memory CD8+ T cells, formed after a
previous wild type AAV infection with Adenovirus co-infection, expanded upon
introduction of the recombinant vector and led to destruction of the transgene-expressing
cells [250].
These results were not reflected in animal models and in fact conflict with some reports on
the immune response to AAV2-mediated gene transfer in mice and non-human primates.
Three separate groups demonstrated that capsid-specific CD8+ T cells were unable to elicit
cytotoxic activity on transduced cells to eliminate transgene expression [251, 252]. Canine
and non-human primate studies have also demonstrated disparities, with some reports of
lack of detectable liver toxicity and no loss in F.IX expression [253, 254] and others
observing inflammation, cell infiltrates, and loss of transgene expression resulting from
intramuscular administration in canines regardless of serotype (AAV2 or AAV6) or
transgene [252].
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These discrepancies highlight the importance of population differences and prior AAV
exposure when considering candidates for AAV-mediated gene therapy. Thus, when
designing vectors for clinical purposes, several aspects should be considered. To escape pre-
existing immunity, AAV2-based vectors will need to be replaced with novel serotypes. By
classic definition, a serotype is a species that cannot be neutralized by the antibodies of any
other sero-type, nor can trigger antibody production that can neutralize any other serotype.
Additionally, an immunologically covert vector would not induce a strong humoral response
leading to NAb production, either from harboring immunodominant epitopes or an
unintentional adjuvant. Therefore, re-administration with the same serotype could become a
possibility. To achieve these desirable properties many groups have tried to identify new
serotypes or modify the capsid with the goal of thwarting pre-existing memory or a robust
immune response while at the same time maintaining infectivity and targeted tropism of the
vector.
7.2. Masking the Capsid Topology through PEGylation
A method to modify the capsid without altering the actual coding sequence is covalent
conjugation of poly-ethylene glycol (PEG). PEGylated Adenovirus has previously been
observed to promote gene expression upon re-administration and evade neutralization by
NAbs (46:23-26). The Adenovirus precedent inspired Le et al. and Lee et al. to experiment
with PEGylation on the AAV capsid. Using succinimidyl propinoic acid, Lee et al.
conjugated various sized PEG chains in a broad range of PEG:capsid ratios and
demonstrated an inverse correlation between chain size and ratio with transduction and NAb
escape [208]. Le et al. PEGylated AAV with three conjugation platforms and identified a
neutralization-escaping variant—AAV2 modified with tresyl chloride PEG—that even
achieved higher levels of transduction in vitro and in vivo than unmodified AAV2 [255].
PEGylation, along with other novel chemical modifications to the capsid, might prove to be
a useful tool in combination with the following methods for immune response-escaping
capsid design. However, changes to tropism and subcellular trafficking must be taken into
consideration, as chemical modifications of surface residues would like lead to alterations in
receptor binding and host-vector interactions.
7.3. Transencapsidated Vectors: Novel Serotypes with Differential Immune Responses
The first attempts at identifying new vectors for gene therapy was simply isolating new
serotypes from humans and nonhuman primates that would escape pre-existing immunity or
cross neutralization with other serotypes (for a review of vector development in AAV1-
AAV8 see [147]. These viruses have been evaluated as transencapsidated vectors, or capsids
of the different serotypes packaging transgenes flanked by AAV2 ITRS. Most work thus far
has investigated AAV2/2, AAV2/1, AAV2/6, and AAV2/5. Murine studies by Xiao et al.
demonstrated that AAV2/1 and AAV2/2 do not cross react when administered in the muscle,
which allows for readministration of the other vector after initial exposure to the first.
Furthermore, in the liver, AAV2 only slightly inhibited readministration with AAV1 [256].
Halbert et al. demonstrated that AAV2/6 was less immunogenic than AAV2/2 and re-
administration with AAV2/6 or an administration of AAV2/6 following AAV2/2 achieved
efficient transduction in mouse lung after intranasal delivery [257]. AAV2/2, AAV2/1, and
AAV2/5 have demonstrated no cross-reactivity to each other [258-260], and AAV 2/5 can
be administered through endotrachael delivery or intramuscularly following prior treatment
with AAV2/2 or AAV2/1 [260]. Additionally, follow-up administration of AAV2/1
intramuscularly upon prior treatment with AAV2/2 or AAV2/5 improved gene transfer
[259]. Furthermore, Gao et al. isolated AAV7 and AAV8 and demonstrated that they were
immunologically distinct from any other serotype [141]. Similarly, Vandendriessche et al.
determined that AAV2/9 andAAV2/8 were minimally immunogenic after systemic
administration in mice [261]. Mayes et al. compared the immune profiles of AAV2/8 and
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non-human primate serotype AAVrh32.33 packaging LacZ reporter genes, which
demonstrated no cross-reactivity and elicited distinct host responses. While AAV8 triggered
a minimal CD4+ and CD8+ T cell response in mice, AAVrh32.33 evoked a robust cellular
response, elevated IFNγ production, and elicited almost 7 fold more LacZ-specific CD8+ T
cells than AAV8, which correlated with a loss of transgene expression [262]. Novel
serotypes may be abundant and demonstrate promise in certain therapeutic settings;
however, different serotypes often use different cellular receptors for entry and thus differ in
tropism and, therefore, may not be appropriate for the same applications. Furthermore, the
use of alternative serotypes does not overcome the formation of immunological memory or
neutralization by pre-existing immunity. Moreover, studies have determined that antibodies
formed after the administration of one serotype can elicit neutralizing effects on a different
serotype in humans [238, 245]. Therefore, other methods are necessary to avoid immune
responses.
7.4. Identification and Disruption of Immunogenic Regions on the AAV Capsid
In order to maintain the tropism for a given cell type but reduce inhibition by NAbs, efforts
have been made to disrupt the known epitopes of the AAV capsid or other not yet known
epitopes. Several immunogenic sites on the AAV2 capsid have been identified [120, 243,
245, 247], with other epitopes being exploited for common AAV2 capsid antibodies A1,
A69, B1, and A20 [244]. Recently, through in vitro PBMC stimulation with a synthetic
peptide library, Madsen et al. discovered 17 common immunodominant MHCI and MHCII
capsid peptides, including 2 located on VP1 and 7 that shared homology to previously
identified sequences. Some epitopes spanned multiple HLA haplotypes, indicating their
prevalence in a capsid immune response [249]. Huttner et al. introduced laminin peptide
insertions within surface loops on the AAV2 capsid. Insertions at residues 261, 534, 573,
and 381 reduced the affinity of the A20 antibody for the capsid, while insertions at positions
534, 573, and 587 reduced the affinity of the C37-B antibody for the capsid. The insertion at
position 587 also achieved neutralizing antibody evasion as human serum did not inhibit
transduction of B16F10 cells [263]. Building on immunogenic residues previously identified
[185, 192], Maersch et al. recently randomized AAV2 residues 449, 458, 459, 551, and 493
in a library essentially representing combinations of all 20 amino acids at all 5 positions.
This library was incubated in neutralizing serum before selection on HEK 293 cells, which
resulted in several “stealth” clones outperforming AAV2 in a transduction assay of HeLa
cells in the presence of neutralizing serum. As immunological pressure was placed on the
library, certain trends favoring some amino acid substitutions were noted. Specifically, small
hydrophilic residues were favored overall and the incidence of an acidic residue at position
551 increased by 2 fold [264].
Oftentimes, intentions of achieving a certain desirable vector trait incidentally yields Nab-
resistant products. For example, Asokan et al. re-engineered the primary heparin sulfate
binding domain of AAV2 in an attempt to design a vector with systemic tropism that was
de-targeted from the liver. Consequently, this basic patch at the 3 fold spikes was replaced
with residues in the same location from other serotypes. AAV2i8 (AAV2 with hexapeptide
585-QQNTAP-590 substituted at this site) not only ablated heparin sulfate binding but also
allowed for persistent, systemic transduction, decreased liver tropism, and evasion from
AAV2 NAbs and human sera [162]. This groups work compliments studies by
Vandenberghe et al., who demonstrated that substituting the heparin sulfate binding motif
RXXR motif of AAV2 into the same region on AAV8 resulted in enhanced CD8+ T cell
activation [265]. The disruption of known receptor binding regions on AAV capsids to
create neutralization-escaping vectors should be explored further, as this is a promising
strategy to create a varity of vectors for given applications that will evade pre-existing
immunity and allow re-administration for gene therapy applications.
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7.5. Directed Evolution of Immunologically Covert Vectors
While rational design to evade capsid neutralization may be feasible in some cases, there are
many challenges to this approach. These include overcoming the prevalence of several
epitopes, some of which are likely conformational, while maintaining infectivity and desired
tropism. To meet these challenges in a rapid, unbiased setting, the directed evolution
approach has been explored as a way to isolate novel, immune response-escaping vectors
(see Non-rational design: Directed Evolution). In the first example of AAV directed
evolution, Maheshri et al. created a library of mutants based on an AAV2 background in an
attempt to recover AAV2-based variants that escaped neutralization. Four clones, all with a
common T716A mutation, demonstrated a 3-fold improvement in NAb evasion. One clone
(r2.15), isolated in a second round of selection, was 96-fold more infectious than AAV2 at
the highest NAb titer tested. r2.15 administration in vivo delivered 23% more erythropoietin
at the same NAb titer that reduced AAV2 delivery to basal levels [192].
Regardless of neutralization pressure, the directed evolution approach often yields
immunologically distinct clones. In addition to isolating a variant specific to a CHO
melanoma cell line, Li et al. demonstrated that chimeric-1829 remained completely unbound
to the A20 antibody, was not cross-reactive with parent serotypes AAV1, AAV8, and
AAV9, and displayed only mild cross-reactivity to AAV2 [195]. Similarly, Koerber et al.
isolated several clones through directed evolution that were more resistant to pooled human
IgGs than AAV1 or AAV2 without selection for NAb evasion [196]. Furthermore, in vivo
selection of a myocardium tropic clone resulted in M41, which demonstrated over 20%
more transduction activity in the presence of pooled human IgG serum than AAV2 does
[201].
Capsid design approaches demonstrate promise in developing novel vectors that will avoid
pre-existing immunity to naturally occurring serotypes. The capsid mutations that have lead
to escape from pre-existing immunity are summarized in Fig. (2D). However, the feasibility
of a second administration of these vectors remains variable, as the natural immune response
will not spare these vectors. Furthermore, several studies have determined that, in addition
to the AAV capsid, the transgene product can elicit an immune response, especially if the
transgene contains alternative reading frames that encode for immunogenic proteins [266].
Therefore, capsid modifications cannot be the only strategy considered to improve vector
efficacy.
7.6. Delivery Strategies to Evade the Immune Response
Extensive research has demonstrated that the route of delivery and destination of the AAV
vector can have variable effects on the resultant immune response. Intramuscular,
intraveneous, intraperitoneal, and subcutaneous administration seem to evoke the most
robust immune response to the capsid and the transgene product [267-271]. Wang et al.
reported that, upon i.m. administration of AAV2 encapsidating F.IX, expansion and
contraction of IgG2 antibodies and prolonged IgG1 activity corresponded to a loss of F.IX
transgene expression [270] and transgene-specific, dose-dependent CD4+ and CD8+ T cell
proliferation corresponding to a loss of Ova expression [271]. In contrast, hepatic delivery
has been observed to elicit a minimal immune response and even induce tolerance and
anergy [269, 270, 272-277]. For example, in mice with CD4+ T cell receptors specific for an
ova peptide, hepatic gene transfer of AAV2 with ova cDNA and an EF1 promoter led to
decreased levels of IL-2 secretion and decreased levels of CD4+ T cells in in vitro ova
stimulated splenocytes and inguinal lymph nodes as compared to hepatic gene transfer of
AAV2 packaging GFP [273]. Furthermore, a general decrease of Ova-specific T cells
coupled with an increase in CD4+CD25+FoxP3+ T cells, CD25+GITR+ T cells, and
CD4+CD25+ T cells was observed [272]. Regardless of tolerance induction, hepatic gene
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transfer has been determined to elicit a T cell independent B cell response leading to NAb
production in Rhesus macaques and mice [268].
Differences in immune activity are even detailed in immunoprivileged sites, which has lent
insight into sub-organ delivery and re-administration timing. In a Phase I study for Canavan
disease, rAAV2 encapsidating aspartoacylase delivered by intracranial administration. Then,
sera was analyzed for Nabs and Nabs were identified in 7 out of 10 subjects with no NAbs
for AAV2, 2 out of 10 subjects with low NAb activity, and 1 subject with a high NAb titer,
which suggested recent exposure to wild type AAV [125]. In attempts to achieve gene
transfer in the eye, Li et al. performed intravitreal and subretinal AAV delivery to mice.
Administration to the vitreous a non-immunopriviledged site, resulted in a humoral
response, which hindered successful transduction to the opposite eye. In contrast, subretinal
administration was permissive to a second round of delivery to the opposite eye or an
intravitreal administration [278]. Mastakov et al. performed re-administration studies in the
rat brain and observed that, while only 3% of initial transduction levels was achieved with a
second administration of AAV2 2 weeks after the initial delivery, 20% of initial transduction
levels could be achieved if the second injection was administered 4 weeks after the initial
delivery. Furthermore, complete restoration of transgene levels could be achieved if the
second injection was delayed to 3 months [279]. In addition, Peden et al. demonstrated that
repeat injections of AAV5 to the brain could be tolerated, and increasing the time interval
between injections to 11 weeks resulted in no loss of transgene expression [280]. Moreover,
Sabatino et al. demonstrated that the host age at the time of administration might be an
important indicator of successful transgene expression. AAV2 encapsidating hF.IX
delivered to adult mice resulted in hF.IX-specific antibodies and no long term hF.IX
expression, where as in utero or neonatal treatment resulted in no detectable antibodies and
long-term hF.IX expression[281].
7.7. Concluding Immune Response Remarks
As more information emerges from AAV clinical trials, it is becoming apparent that a more
comprehensive investigation into the immune response elicited by AAV might be necessary
to improve vector efficacy. Thus, the design of future vectors must include solutions to
factors such as prior exposure in patient samples, prevalence of immunodominant epitopes
on the capsid surface, and the route of vector delivery. Several reports have suggested that
transient immuno-suppression reduces NAb proliferation and prolongs transgene expression
[282-284]. However, immunosuppression may not be a favorable option for many patients.
A recent study has demonstrated that the kinetics of transgene expression might play a role
in the emergence of immunity [266]. Thus, self-complimentary vectors, which allow for
more rapid transduction as they bypass second strand synthesis (the rate-limiting step in
transgene expression) [108], might be an advantageous strategy. However, the limitations on
packaging size implicated in self-complimentary vectors must be considered. Improvements
in AAV safety to avoid humoral and cellular immunity will be ongoing as more information
from clinical trials becomes available.
8. CONCLUDING REMARKS
As research progresses, the steps necessary to making adeno-associated virus a safe,
effective gene delivery vehicle are becoming clear. Significant advances have been made
with methods to create efficient, cell-specific targeting vectors in vitro, and these methods
are now being applied to the in vivo setting to enhance therapeutic success. Our
understanding of the immune system's relationship with AAV vectors has allowed for both
the creation of vectors that are unable to be recognized and cleared from the body as well as
delivery strategies to minimize the immune response. In the future, many new capsids will
be developed that can simultaneously hide from the immune system and seek intended target
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tissues, but our greater understanding of vector biology will allow for the development of
transgene design strategies synergistic with capsid design – such as clever design of the
transgene in both enhancing target selectively through promoter choice as well as increasing
genomic pay-load [285]. Furthermore, as we continue to evolve a comprehensive view of
what is necessary to optimize AAV as a smart vector we can improve therapeutic safety,
such as by preventing vector mobilization into the population [286]. In addition to vector
design, as our understanding of AAV's intracellular biology advances we are also
discovering new ways of enhancing gene expression, such as through the use of small
molecules to inhibit proteasomal degradation of the particle [78]. In conclusion, though we
have already seen great success with AAV-mediated gene therapy in both the laboratory and
the clinic, the future of the clinical therapy holds even greater promise.
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Past and Current Clinical Trials Utilizing rAAV. The percentage of clinical trials using
rAAV (A) in different categories of disease, (B) in different phases, and (C) using capsids of
different serotypes of AAV. Other serotypes includes AAV8, AAV2.5, AAV6, and AAVrh.
10. Clinical trial data was compiled from the Gene Therapy Clinical Trials Worldwide
Database (http://www.wiley.co.uk/genetherapy/clinical).
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Representation of various strategies to modify AAV capsids for tissue targeting and immune
evasion. A. Example of a mosaic virus, where plasmids encoding for the capsids of two
different serotypes are combined in a molar ratio of 1:5 , AAVx; , AAVy. B. Example of
a chimeric virus (adapted from chimeric-1829 [195]). , AAV1; , AAV8; , AAV2; ,
AAV9. C. Combinatorial representation of human and murine antibody and cell mediated
epitopes of AAV serotypes displayed on an AAV2 background. , , , [243]; , [246]; ○,
[244]; , [238]; , [245]; , [247]; , AAV2 background. D. Capsid modifications
rendering ability to escape neutralization displayed on an AAV2 background. , [264]; ,
[162]; , [208]; , [263]; , AAV2 background. The available structure of the AAV2
monomer (PDB accession no. 1LP3) was supplied as a template for capsid generation.
Capsid features were rendered using PyMOL (http://pymol.sourceforge.net). For figure 2a,
monomers were structurally aligned to an AAV2 template using PyMOL. For figure 2b-d,
AAV2 models were generated with VIPER [287].
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